haloperidol has been researched along with Cronkhite-Canada Syndrome in 1 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Cronkhite-Canada Syndrome: A nonfamilial polyposis syndrome that is characterized by the presence of diffuse gastrointestinal polyposis, DIARRHEA, and PROTEIN-LOSING ENTEROPATHY. It was first reported by Cronkhite and Canada in 1955.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Peitl, A | 1 |
Vucić Peitl, M | 1 |
Pavlović, E | 1 |
Ljubicić, D | 1 |
1 other study available for haloperidol and Cronkhite-Canada Syndrome
Article | Year |
---|---|
Acute brain syndrome as a consequence of the Cronkhite-Canada syndrome.
Topics: Acute Disease; Aged; Dementia; Drug Therapy, Combination; Female; Haloperidol; Humans; Intestinal Po | 2005 |